Jonathan Rubin, MD

Jonathan Rubin, MD

Senior Vice President, Chief Medical Officer Research and DevelopmentatSupernus Pharmaceuticals· In proxies 2021–2025

Pay in FY2025Supernus Pharmaceuticals stock +37.4% the same year

Jonathan Rubin, MD was paid $1.4M in FY2025 (Dec). Supernus Pharmaceuticals stock rose 37.4% that year.

Pay$100 in the stock at the end of FY20 → $158
Pay is from the Summary Compensation Table of each Supernus Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Supernus PharmaceuticalsPublic company · 5 yr
    • Senior Vice President, Chief Medical Officer Research and Development2021 – Present · 5 yrStock in role +60%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?